Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

However, it turns out that anyone can be affected by hemophilia. Hemophilia could potentially develop in every ten-thousandth newborn. Intriguingly, women act as asymptomatic carriers, with the ...

Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with hemophilia A, the most common form of hemophilia. The research team was able to show ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...